The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[Perindopril co-treated with AM6545] inhibits the reaction [Streptozocin results in increased expression of AGTR1A protein]; AM6545 inhibits the reaction [Streptozocin results in increased expression of AGTR1A mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of AGTR1A protein]
AM6545 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of ARG1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in decreased expression of ARG1 mRNA]; Perindopril inhibits the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of ARG1 mRNA]]
[AM6545 co-treated with Perindopril] inhibits the reaction [Streptozocin results in increased expression of CCL2 mRNA]; [AM6545 co-treated with Perindopril] inhibits the reaction [Streptozocin results in increased expression of CCL2 protein]
AM6545 inhibits the reaction [Streptozocin results in increased expression of CCL3 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of CCL3 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of CCL3 mRNA]]
[AM6545 co-treated with Perindopril] inhibits the reaction [Streptozocin results in increased expression of CCR2 mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of CCR2 mRNA]
AM6545 inhibits the reaction [Streptozocin results in decreased expression of CD163 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of CD163 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of CD163 mRNA]]
AM6545 inhibits the reaction [Streptozocin results in increased expression of CD68 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of CD68 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of CD68 mRNA]]
AM6545 affects the reaction [Ethanol affects the expression of CNR1 protein] [Ethanol co-treated with AM6545] results in increased expression of CNR1 protein
AM6545 affects the reaction [Ethanol affects the expression of CNR2 protein] [Ethanol co-treated with AM6545] results in increased expression of CNR2 protein
[AM6545 co-treated with Perindopril] inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of FN1 protein]
AM6545 inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]]
AM6545 inhibits the reaction [Streptozocin results in decreased expression of MRC1 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of MRC1 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of MRC1 mRNA]]
AM6545 inhibits the reaction [Streptozocin results in increased expression of NOS2 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of NOS2 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of NOS2 mRNA]]
AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS1 protein]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of NPHS1 mRNA]]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of NPHS1 protein]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS1 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS1 protein]]
AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS2 mRNA]; AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS2 protein]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of NPHS2 mRNA]]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of NPHS2 protein]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS2 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS2 protein]]
AM6545 inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of TNF protein]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of TNF protein]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of TNF protein]]
danuglipron results in increased activity of GLP1R protein [danuglipron results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
1-Deoxynojirimycin inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]; 1-Deoxynojirimycin inhibits the reaction [Tunicamycin results in increased activity of CASP3 protein]
1-Deoxynojirimycin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; 1-Deoxynojirimycin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of FBP2 protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of G6PC1 protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GCK protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of and results in decreased secretion of INS1 protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of INSR protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of LPL mRNA]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PCX protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PCK1 protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PDK1 mRNA]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PFKP protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PKLR protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL18 protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL18 protein]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL1B protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL1B protein]
Chloroquine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]]; ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein] Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]] ginsenoside Rb1 results in decreased expression of SQSTM1 protein
[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein
AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of CD86 protein]; AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of ITGAX protein] indirubin-3'-monoxime binds to and results in increased activity of AHR protein indirubin-3'-monoxime binds to AHR protein
indirubin-3'-monoxime promotes the reaction [tetraarsenic tetrasulfide results in increased expression of AQP9 mRNA]; indirubin-3'-monoxime promotes the reaction [tetraarsenic tetrasulfide results in increased expression of AQP9 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD40 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein] indirubin-3'-monoxime results in decreased expression of CD40 protein
indirubin-3'-monoxime results in increased expression of CD80 protein [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased expression of CD80 protein; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased expression of CD80 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD86 protein; AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of CD86 protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in increased expression of CYP1A1 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP1A1 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP1A1 protein indirubin-3'-monoxime results in increased expression of CYP1A1 mRNA indirubin-3'-monoxime results in increased expression of CYP1A1 protein
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in decreased expression of HSPA2 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA2 mRNA
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA9 mRNA indirubin-3'-monoxime results in increased expression of HSPA9 mRNA
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of ICAM1 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] indirubin-3'-monoxime results in decreased expression of ICAM1 protein
indirubin-3'-monoxime results in increased expression of IDO1 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of IDO1 protein]
indirubin-3'-monoxime results in increased expression of IDO2 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of IDO2 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased secretion of IL10 protein; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] indirubin-3'-monoxime results in decreased secretion of IL10 protein
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of IL1B protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
indirubin-3'-monoxime results in decreased expression of IL27 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of IL27 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of IL6 protein; [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of IL6 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of ITGAX protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAX protein]
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in decreased expression of NFKBIA mRNA
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 protein
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased activity of RELA protein indirubin-3'-monoxime results in decreased activity of RELA protein
indirubin-3'-monoxime results in increased expression of TGFB2 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB2 protein]
indirubin-3'-monoxime results in increased expression of TGFB3 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB3 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of TNF protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat results in increased activity of CFTR protein mutant form]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]; miglustat inhibits the reaction [CANX protein binds to CFTR protein mutant form]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]
miglustat inhibits the reaction [[ST8SIA1 protein affects the abundance of Gangliosides] which results in decreased expression of PAWR protein]; miglustat inhibits the reaction [ST8SIA1 protein results in increased expression of BCL2 protein]
[miglustat results in decreased activity of UGCG protein] which results in decreased abundance of Gangliosides; [miglustat results in decreased activity of UGCG protein] which results in decreased abundance of Glucosylceramides
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] Orlistat results in decreased expression of ACACA mRNA
orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid]
orlistat results in increased activity of CASP3 protein orlistat results in increased cleavage of CASP3 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA]
orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA]
Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein] Orlistat results in decreased expression of CAT protein
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein] orlistat results in decreased secretion of CCK protein
Orlistat results in increased expression of CCND1 protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]
Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
orlistat results in increased phosphorylation of EIF2A protein orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]
EIF2AK3 gene mutant form results in increased susceptibility to orlistat orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]
ERBB2 protein affects the susceptibility to orlistat orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein orlistat affects the localization of ERBB2 protein
orlistat analog binds to FASN protein FASN protein affects the susceptibility to orlistat [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [Orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; Orlistat binds to and results in decreased activity of FASN protein; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone] orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein [orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid] Orlistat results in decreased expression of FASN protein
orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein] orlistat results in decreased expression of GCG protein orlistat results in decreased secretion of GCG protein
orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein]
orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]
orlistat results in decreased expression of INS protein orlistat results in increased expression of INS protein orlistat affects the expression of INS protein [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
orlistat results in decreased activity of LPL protein orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein] [orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 mRNA] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA
Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein]
Orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; Orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein]
orlistat results in decreased activity of PLA2G7 protein [orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein
orlistat results in decreased secretion of PNLIP protein orlistat results in decreased activity of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein] orlistat affects the folding of PNLIP protein [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil]
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]
orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein] orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein]
Orlistat results in increased expression of PTEN protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]
orlistat results in decreased secretion of PYY protein orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein]
[orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein orlistat results in decreased expression of SKP2 protein
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein] Orlistat results in decreased expression of SREBF1 protein
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF protein]
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]
resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D2 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Rimonabant inhibits the reaction [MIR762 mRNA results in decreased expression of AGAP2 mRNA]; Rimonabant promotes the reaction [Dietary Fats results in increased expression of AGAP2 mRNA] Rimonabant results in increased expression of AGAP2 mRNA
Rimonabant inhibits the reaction [Dronabinol results in decreased phosphorylation of AKT1 protein] Rimonabant inhibits the reaction [Dronabinol results in increased phosphorylation of AKT1 protein]; Rimonabant inhibits the reaction [methanandamide results in increased phosphorylation of AKT1 protein]
Rimonabant inhibits the reaction [1-pentyl-3-(1-naphthoyl)indole promotes the reaction [ARRB2 protein binds to CNR1 protein]]; Rimonabant inhibits the reaction [1-pentyl-3-(1-naphthoyl)indole promotes the reaction [ARRB2 protein binds to CNR2 protein]]
Rimonabant inhibits the reaction [forsythiaside inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of BAX protein]] Rimonabant inhibits the reaction [Cannabidiol results in decreased expression of BAX protein]
Rimonabant inhibits the reaction [forsythiaside inhibits the reaction [amyloid beta-protein (25-35) results in decreased expression of BCL2 protein]]; Rimonabant inhibits the reaction [LEP gene mutant form results in decreased expression of BCL2 protein]
Rimonabant inhibits the reaction [XLR-11 results in increased activity of CASP3 protein] Rimonabant inhibits the reaction [forsythiaside inhibits the reaction [amyloid beta-protein (25-35) results in increased cleavage of CASP3 protein]]; Rimonabant inhibits the reaction [JZL 184 inhibits the reaction [Sulfur Dioxide results in increased cleavage of and results in increased activity of CASP3 protein]]
Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2] Rimonabant results in decreased expression of CCL2 mRNA
Rimonabant inhibits the reaction [[Ethanol results in increased activity of CDK5 protein] which results in increased degradation of CDK5R1 protein]; Rimonabant inhibits the reaction [Ethanol results in increased activity of CDK5 protein]
1-(4-chlorophenyl)-3-(3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl)urea analog inhibits the reaction [Rimonabant binds to CNR1 protein]; 1-(4-chlorophenyl)-3-(3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl)urea inhibits the reaction [Rimonabant binds to CNR1 protein]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Rimonabant binds to CNR1 protein]; 5F-CUMYL-PICA inhibits the reaction [Rimonabant binds to CNR1 protein]; AM 6527 inhibits the reaction [Rimonabant binds to CNR1 protein]; arachidonyl dopamine inhibits the reaction [Rimonabant binds to CNR1 protein]; Dronabinol inhibits the reaction [Rimonabant binds to CNR1 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate analog inhibits the reaction [Rimonabant binds to CNR1 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate inhibits the reaction [Rimonabant binds to CNR1 protein]; N'-((3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide affects the reaction [Rimonabant binds to CNR1 protein]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [Rimonabant binds to CNR1 protein]; Rimonabant binds to and results in decreased activity of CNR1 protein; Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of CNR1]; Rimonabant inhibits the reaction [1-pentyl-3-(1-naphthoyl)indole promotes the reaction [ARRB2 protein binds to CNR1 protein]]; Rimonabant inhibits the reaction [1-pentyl-3-(1-naphthoyl)indole results in increased activity of CNR1 protein]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [Dronabinol results in increased expression of CNR1 mRNA]; Rimonabant inhibits the reaction [HU 211 results in increased activity of CNR1] Rimonabant results in decreased activity of CNR1 protein Rimonabant affects the localization of CNR1 protein Rimonabant results in decreased expression of CNR1 mRNA [Rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; [Rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to palmidrol analog; Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]]; Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]; Rimonabant binds to and results in decreased activity of CNR1 protein; Rimonabant inhibits the reaction [1-(5-fluoropentyl)-3-(1-naphthoyl)indole analog binds to CNR1 protein]; Rimonabant inhibits the reaction [1-(5-fluoropentyl)-3-(1-naphthoyl)indole binds to CNR1 protein]; Rimonabant inhibits the reaction [[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in decreased abundance of Nitric Oxide]; Rimonabant inhibits the reaction [Dronabinol results in increased activity of CNR1 protein] 6-methyl-3-(2-nitro-1-(thiophen-2-yl)propyl)-2-phenyl-1H-indole inhibits the reaction [Rimonabant binds to CNR1 protein]; [Rimonabant binds to and results in decreased activity of CNR1 protein] which affects the expression of FOS protein; [Rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to Nicotine; Rimonabant binds to and results in decreased activity of CNR1 protein; Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein]; Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CNR1 mRNA]; Rimonabant inhibits the reaction [5F-ADB cannabinoid binds to and results in increased activity of CNR1 protein]; Rimonabant inhibits the reaction [5F-ADB cannabinoid metabolite binds to and results in increased activity of CNR1 protein]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; Rimonabant inhibits the reaction [HU 211 binds to and results in increased activity of CNR1 protein]
Rimonabant inhibits the reaction [1-pentyl-3-(1-naphthoyl)indole promotes the reaction [ARRB2 protein binds to CNR2 protein]]; Rimonabant inhibits the reaction [1-pentyl-3-(1-naphthoyl)indole results in increased activity of CNR2 protein]
Rimonabant inhibits the reaction [Dronabinol results in increased phosphorylation of CREB1 protein] Rimonabant inhibits the reaction [Dronabinol results in decreased expression of and results in decreased phosphorylation of CREB1 protein]
Rimonabant results in decreased expression of CRH mRNA Dronabinol affects the reaction [Rimonabant results in decreased expression of CRH mRNA]; Rimonabant inhibits the reaction [HU 211 results in decreased expression of CRH mRNA]
Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CXCL10]
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Rimonabant] affects the expression of FAAH mRNA FAAH affects the reaction [Rimonabant affects the expression of CARTPT protein]; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide]
Rimonabant inhibits the reaction [Dronabinol results in increased expression of FOS protein] [Rimonabant binds to and results in decreased activity of CNR1 protein] which affects the expression of FOS protein; Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of FOS protein]
Rimonabant inhibits the reaction [Dronabinol results in decreased expression of GRIA1] Rimonabant inhibits the reaction [Dronabinol results in decreased expression of GRIA1 mRNA]
Rimonabant results in decreased expression of ICAM1 protein Rimonabant inhibits the reaction [Glucose results in increased expression of ICAM1 protein]
Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]]; Rimonabant inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of NOS2 mRNA]; Rimonabant inhibits the reaction [Cannabinol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]
Rimonabant inhibits the reaction [Dronabinol promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL10 protein]]
[Rimonabant co-treated with SR 144528] inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of IL1B]; Rimonabant inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Rimonabant promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
Rimonabant inhibits the reaction [Dietary Fats results in increased expression of INS1 protein]; Rimonabant inhibits the reaction [Dietary Fats results in increased secretion of INS1 protein]; Rimonabant inhibits the reaction [LEP gene mutant form results in decreased expression of INS1 protein] Rimonabant results in decreased expression of INS1 protein
Rimonabant results in increased expression of KLF4 mRNA MIR466J mRNA affects the reaction [Rimonabant results in increased expression of KLF4 mRNA]; Rimonabant inhibits the reaction [Dietary Fats results in decreased expression of KLF4 mRNA]
Rimonabant inhibits the reaction [Dietary Fats results in increased secretion of LEP protein]; Rimonabant inhibits the reaction [LEP gene mutant form results in decreased expression of BCL2 protein]; Rimonabant inhibits the reaction [LEP gene mutant form results in decreased expression of CCND2 protein]; Rimonabant inhibits the reaction [LEP gene mutant form results in decreased expression of INS1 protein]
Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [delta(9)-tetrahydrocannabinolic acid results in increased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [methanandamide results in increased phosphorylation of MAPK1 protein] Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [Dronabinol results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [Dronabinol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] Rimonabant affects the localization of MAPK1 protein Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [Dronabinol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [HU 211 results in increased phosphorylation of MAPK1 protein] Rimonabant results in decreased activity of MAPK1 protein
Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [Dronabinol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [HU 211 results in increased phosphorylation of MAPK3 protein] Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [Dronabinol results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [Dronabinol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] Rimonabant results in decreased activity of MAPK3 protein Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [delta(9)-tetrahydrocannabinolic acid results in increased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [methanandamide results in increased phosphorylation of MAPK3 protein] Rimonabant affects the localization of MAPK3 protein
Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased phosphorylation of MAPK8 protein]; Rimonabant inhibits the reaction [HU 211 results in increased phosphorylation of MAPK8 protein]
Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of MBP protein]
Rimonabant inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein]
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Rimonabant] affects the expression of NAPEPLD mRNA
Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of NLRP3] Rimonabant inhibits the reaction [Cannabidiol results in decreased expression of NLRP3 protein]
[Rimonabant co-treated with SR 144528] inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Rimonabant inhibits the reaction [Dietary Fats results in increased expression of NOS2]; Rimonabant promotes the reaction [PF 3845 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Rimonabant inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of NOS2 mRNA]
Rimonabant affects the reaction [Dietary Fats affects the expression of NTN1 protein]; Rimonabant inhibits the reaction [Dietary Fats results in increased expression of NTN1 mRNA]; Rimonabant inhibits the reaction [MIR762 mRNA results in increased expression of NTN1 mRNA] Rimonabant results in decreased expression of NTN1 mRNA
Rimonabant results in decreased expression of PLIN2 protein Rimonabant inhibits the reaction [Oleic Acid results in increased expression of PLIN2 protein]
Rimonabant inhibits the reaction [Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]] Dronabinol affects the reaction [Rimonabant results in increased expression of PRL protein]; Rimonabant inhibits the reaction [Dronabinol results in decreased expression of PRL protein]
Rimonabant affects the expression of PTEN mRNA [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Rimonabant] affects the expression of PTEN mRNA
Rimonabant inhibits the reaction [forsythiaside inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of PTGS2 protein]]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; Rimonabant inhibits the reaction [JZL 184 inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]
Rimonabant inhibits the reaction [Ethanol promotes the reaction [EHMT2 protein binds to RAC1 promoter]]; Rimonabant inhibits the reaction [Ethanol results in decreased expression of RAC1 protein]
Rimonabant inhibits the reaction [Dronabinol results in increased localization of RAF1 protein]; Rimonabant inhibits the reaction [methanandamide results in increased localization of RAF1 protein]
Rimonabant inhibits the reaction [JZL 184 inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] Rimonabant results in decreased expression of RELA protein
[MIR466J mRNA co-treated with Rimonabant] affects the expression of STAT6 mRNA; Rimonabant inhibits the reaction [Dietary Fats results in decreased expression of STAT6 mRNA]
Rimonabant affects the reaction [PRKN mutant form affects the activity of TH protein]; Rimonabant inhibits the reaction [Dronabinol results in increased activity of TH protein] Rimonabant results in increased activity of TH protein
Rimonabant inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of TNF]; Rimonabant inhibits the reaction [forsythiaside inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein]] Rimonabant results in decreased expression of TNF mRNA
Rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Rimonabant inhibits the reaction [Capsaicin binds to and results in increased activity of TRPV1 protein]; Rimonabant inhibits the reaction [N-(4-hydroxyphenyl)arachidonylamide binds to and results in increased activity of TRPV1 protein]
Rimonabant inhibits the reaction [Glucose results in increased expression of VCAM1 protein] Rimonabant results in decreased expression of VCAM1 protein
Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of and results in decreased secretion of VEGFA protein]
Rimonabant results in increased expression of XBP1 mRNA [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of XBP1 mRNA alternative form]; Gemcitabine promotes the reaction [Rimonabant results in increased expression of XBP1 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Calcimycin] inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; semaglutide inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
[Tetradecanoylphorbol Acetate co-treated with Calcimycin] inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; semaglutide inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]
semaglutide inhibits the reaction [Lipopolysaccharides results in increased expression of HDAC5 protein] [Tetradecanoylphorbol Acetate co-treated with Calcimycin] inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased expression of HDAC5 protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; semaglutide inhibits the reaction [Lipopolysaccharides results in increased expression of HDAC5 protein]
[Tetradecanoylphorbol Acetate co-treated with Calcimycin] inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; semaglutide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] semaglutide inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
[Tetradecanoylphorbol Acetate co-treated with Calcimycin] inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; semaglutide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
[Tetradecanoylphorbol Acetate co-treated with Calcimycin] inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]]; semaglutide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]
semaglutide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [Tetradecanoylphorbol Acetate co-treated with Calcimycin] inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; HDAC5 protein inhibits the reaction [semaglutide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; semaglutide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
sibutramine results in decreased activity of CYP2B6 protein sibutramine inhibits the reaction [CYP2B6 protein results in increased hydroxylation of Bupropion]
3,3',5-triiodothyroacetic acid promotes the reaction [THRA protein binds to NCOA2 protein]; 3,3',5-triiodothyroacetic acid promotes the reaction [THRB protein binds to NCOA2 protein]
3,3',5-triiodothyroacetic acid binds to and results in increased activity of NR1I2 protein; [3,3',5-triiodothyroacetic acid results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
MED1 protein promotes the reaction [3,3',5-triiodothyroacetic acid results in increased activity of THRA protein] 3,3',5-triiodothyroacetic acid binds to and results in increased activity of THRA protein; 3,3',5-triiodothyroacetic acid promotes the reaction [THRA protein binds to NCOA2 protein]
3,3',5-triiodothyroacetic acid results in increased activity of THRB protein 3,3',5-triiodothyroacetic acid binds to THRB protein 3,3',5-triiodothyroacetic acid binds to and results in increased activity of THRB protein; 3,3',5-triiodothyroacetic acid promotes the reaction [THRB protein binds to NCOA2 protein]
chromium tripicolinate affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]; chromium tripicolinate affects the reaction [INS1 protein affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; INS1 protein affects the reaction [chromium tripicolinate affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]
chromium tripicolinate results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [chromium tripicolinate results in increased activity of CASP3 protein]
chromium tripicolinate inhibits the reaction [Alloxan results in decreased activity of CAT protein]; chromium tripicolinate inhibits the reaction [Streptozocin results in decreased activity of CAT protein] chromium tripicolinate results in decreased activity of CAT protein
chromium tripicolinate affects the reaction [INS1 protein affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; chromium tripicolinate promotes the reaction [INS1 protein results in increased phosphorylation of IRS1 protein]; INS1 protein affects the reaction [chromium tripicolinate affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]
browse the term
